Table 1 Patient demographics

From: Gemcitabine plus selinexor in selective advanced sarcomas: a phase I of the Spanish group for research on sarcoma study

Characteristics

N (%)

Median age (range)

50 (22–71)

Sex (M/F)

9 (53%)/8 (47%)

Extension at diagnosis:

 - Localized

9 (53%)

 - Locally advanced

2 (12%)

 - Metastatic

6 (35%)

ECOG baselinea:

 - 0

14 (82%)

 - 1

3 (18%)

Extension at baselinea:

 

 - Locally advanced

2 (12%)

 - Metastatic

15 (88%)

Median metastasis-free intervalb (range) (all patients)

11.9 (0–118.5)

Median metastasis-free intervalb (range) (metastatic only)

11.2 (0–118.5)

Median previous lines (range)

1 (1–2)

Histology:

 - Leiomyosarcoma

9 (53%)

 - Osteosarcoma

6 (35%)

 - Alveolar soft part sarcoma

1 (6%)

 - Synovial sarcoma

1 (6%)

  1. aBaseline refers as measurements and observations at the time of patient enrollment, before any intervention of the study.
  2. bThe metastasis-free interval is the time elapsed from initial localized diagnosis until the disease becomes advanced (metastatic or locally inoperable). If advanced at diagnosis, this interval is zero. M male; F female.
Back to article page